We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals

30 hedge funds and large institutions have $1.86M invested in NRX Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more capital invested

Capital invested by funds: $965K → $1.86M (+$893K)

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0.03% more ownership

Funds ownership: 0.45%0.47% (+0.03%)

12% less funds holding

Funds holding: 3430 (-4)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
30
Holders Change
-4
Holders Change %
-11.76%
% of All Funds
0.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
7
Reduced
4
Closed
8
Calls
$58K
Puts
Net Calls
+$58K
Net Calls Change
+$17K

NRXP Hedge Fund Activity: Q4 2023 in Review

30 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2023, worth a combined $1.86M — up 93% from $965K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of NRXP and 4 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 7 added.

The largest buyer was AdvisorShares Investments, opening a new position worth an estimated $212K. The largest seller was Sabby Management, exiting entirely with an estimated $84.5K sold.

  • 30 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2023, down from 34 in Q3 2023.
  • Funds reported $1.86M of NRX Pharmaceuticals stock for Q4 2023, up 93% quarter-over-quarter.
  • 4 funds opened new NRX Pharmaceuticals positions in Q4 2023 and 8 closed out, a net change of -4 holders.
  • The largest NRX Pharmaceuticals buyer in Q4 2023 was AdvisorShares Investments, an estimated $212K added.
  • The largest NRX Pharmaceuticals seller in Q4 2023 was Sabby Management, an estimated $84.5K sold.

Based on aggregated 13F filings for Q4 2023.